Business Wire

CA-INGRAM-MICRO

8.6.2021 19:06:08 CEST | Business Wire | Press release

Share
Ingram Micro’s IT Channel Partners Gain an Advantage with “Core to Edge” Advanced Solutions for Securing and Managing the Distributed Enterprise

Ingram Micro Inc. ’s multi-million-dollar investments within its global Advanced Solutions organization are resulting in new and innovative business resources, opportunities, services and solutions for IT channel partners in more than 122 countries. As part of its efforts, the industry leader is also continuing to modernize its processes and systems enabling channel partners to benefit from and provide a more exceptional customer experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005190/en/

“Our global Advanced Solutions organization continues to give our channel partners a clear advantage in the markets they serve locally and globally,” says Paul Bay, executive vice president and president, Global Technology Solutions, Ingram Micro. “We’re continuing to invest in and serve as a business partner to solution providers, as well as Managed Services and cloud providers, giving them more innovative ways to run their businesses better, grow markets faster and do more for their customers. We’ve also made it easier for technology manufacturers, cloud and software companies to have an efficient, high impact sales channel with multiple routes to market worldwide.”

Ingram Micro’s Advanced Solutions is a worldwide organization anchored by eight global Centers of Excellence (COEs) and thousands of specialists and solutions architects spanning 122 countries. The worldwide business engages with more than 180 emerging and established vendor partners and operates throughout Asia Pacific (APAC), North America, Latin America, Europe, Middle East and Africa (EMEA).

Over the last three years, Ingram Micro’s Advanced Solutions organization enabled thousands of midsized and small business channel partners to offer a variety of technology solutions including Artificial Intelligence, Cloud, Data Center, IoT, Security and UCaaS technologies. And, within the last 18 months, the organization has achieved major milestones including:

  • Established an innovative Ingram Micro Financial Solutions’ global team ready to design ways to boost cashflow by allowing businesses to buy cloud and consumption licenses together with technology product to consume technology as an operating expense, and an agile credit organization granting auto-credit increases for loyal Ingram Micro channel partners.
  • A custom program for new and emerging manufacturers or providers of enterprise-grade technology solutions and services, such as its most recent global announcement with UiPath
  • Record growth of nearly 30% with Cybersecurity solutions from more than 80 providers and IT channel ecosystem partners, including the industry’s most valuable Cybersecurity companies , and groundbreaking Ingram Micro software solutions currently under pilot in EMEA.
  • Additions to the Business Transformation Centers in Buffalo, NY and recently launched Center in Singapore, showcasing exclusive Ingram Micro-bundled Advanced Solutions, which include in-house consultative professional experts and services, in addition to proof-of-concept demonstrations for business decision-makers.
  • Debut of the UCC Center of Excellence in EMEA, which served as a lifeline for channel partners across EMEA supplying Unified Communications and UCaaS during the pandemic.
  • Expanded Data Center Managed and Professional Services, which give channel partners an easier way to market, sell and support a full solution stack on premise, hybrid and in the cloud.
  • Launch of Ingram Micro’s IoT Innovation Lab and Virtual Experience team based in Irvine, CA, providing a fast-track to IoT solutions adopted by local governments, healthcare, and manufacturing.
  • Dozens of industry accolades locally, regionally and globally for its excellence in execution including Distributor of the Year and Partner of the Year in 2020 and 2021 .

“Last quarter we had a number of strategic vendors sign new agreements in Latin America, North America and APAC to ensure channel partners have an expert level of support for their solutions,” says Advanced Solutions leader Sabine Howest, vice president, Global Partner Engagement and IoT, Ingram Micro.

Additionally, new investments are being made to enhance Ingram Micro’s expertise across the board and in specific categories including robotics and automation, as well as IoT and Artificial Intelligence.

“We’re assembling an ecosystem of valuable partnerships, combined with experts only Ingram Micro can provide to make it easier for our channel partners to go-to-market in a more agile way with modern technology solutions,” says Howest. “More and more channel partners and providers are using our COEs to build unique, global go-to-market teams and alliances to support their solutions and services. 2020 brought us closer to our partners and providers, together we grew stronger and accomplished more than we ever imagined. This year we’ve set the bar high to invest in our partners and give them an even stronger advantage.”

For more information, Ingram Micro channel partners are encouraged to connect with their sales representatives. Click here to learn more about Ingram Micro Advanced Solutions.

About Ingram Micro

Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/IngramMicroLatinAmericaDivision

https://www.facebook.com/IngramTechSol

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye